Clinical trials: GRN Related Frontotemporal Dementia
Primary Progressive Aphasia, Semantic Dementia
Treatment for Speech and Language in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain.
- Conditions
- Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia
- Trial name
- NCT04881617
- Testing
- Lexical Retrieval Training (LRT), Video-Implemented Script Training for Aphasia (VISTA)
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Frontotemporal Dementia
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
- Trial name
- NCT04374136
- Testing
- Part 1 Blinded - AL001, Part 2 (OLE Treatment) - AL001
- Where
- 44 sites in United States, Argentina and 14 more
- Volunteers
- 119 people
- Sponsor
- Alector Inc.
Dementia Frontotemporal
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101…
- Trial name
- NCT07154485
- Testing
- NS101 IV infusion
- Volunteers
- 15 people
- Sponsor
- Hee-Jin Kim
Primary Progressive Nonfluent Aphasia
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia.
- Trial name
- AIDA (NCT03174886)
- Testing
- AADvac1 40 µg, AADvac1 160 µg
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Axon Neuroscience SE
Alzheimer Disease
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across…
- Trial name
- NCT03706261
- Testing
- 18F-MK-6240, 18F-Florbetaben
- Where
- United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Adam Brickman
ALS, FTD
Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach
The goal of this study is to learn from discordant twins affected by Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia the contribution of genetic background versus environmental exposure.
- Trial name
- GENIALITY (NCT06595212)
- Testing
- multiomic profile to assess genetic and environmental risk factiors
- Where
- 3 sites in Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Frontotemporal Dementia, Caregiver Burden
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons…
- Conditions
- Frontotemporal Dementia, Caregiver Burden, Primary Progressive Aphasia (PPA), Corticobasal Syndrome
- Trial name
- STELLA-FTD (NCT06613204)
- Testing
- STELLA-FTD Control, STELLA-FTD Test
- Where
- United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Corticobasal Syndrome, Progressive Supranuclear Palsy
Diagnosing Frontotemporal Lobar Degeneration
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
- Conditions
- Corticobasal Syndrome, Progressive Supranuclear Palsy, Behavioral Variant Frontotemporal Dementia, Semantic Dementia
- Trial name
- NCT02964637
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Time of Death
Estimate of the TSD Based on the Quantification of the Tau Protein in CSF
Background: The accurate estimation of the time of death is a challenge in forensic medicine, as the methods routinely used to assess the post-mortem interval (PMI) are far from being precise.
- Trial name
- NCT03845439
- Testing
- Lumbar puncture
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Alzheimer's Disease, Parkinson's Disease
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration
The aim of this study is to compare personality and social cognition changes, including emotion detection and self-awareness, and neuroanatomical correlates in patients, and how that affects the caregiver-patient relationship.
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Frontotemporal Lobar Degeneration
- Trial name
- NCT02964611
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
ALS
Amyotrophic Lateral Sclerosis (ALS) Families Project
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses.
- Trial name
- NCT03865420
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Columbia University
Frontotemporal Dementia
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
This study will evaluate the effects on emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in patients with FTD and healthy controls.
- Trial name
- IEMO (NCT01937013)
- Testing
- Intranasal oxytocin, Saline Nasal Mist
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease
- Trial name
- NCT01459302
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
- Trial name
- NCT02327845
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- University of Miami
Alzheimer Disease, Semantic Dementia
Memory and Social Interactions
Memory and social interaction are intimately linked. On the one hand, social interaction is a privileged context for learning, and on the other hand, appropriate social interactions involve remembering the partners encountered…
- Trial name
- MEM&SO (NCT05800028)
- Testing
- Learning new information
- Where
- France
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.